Discussion of CytoDyn’s Leronlimab As Treatment for Critically Ill COVID Patients Will Be a Focus of One-Hour News Segment on Philippines TV Tonight (Sunday, 8 pm EDT)

On May 7, 2021, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced todaythat its drug candidate, leronlimab, will be featured in a one-hour news segment on Sunday, May 9, at 5:00 pm PDT / 8:00 pm EDT on OneNews in the Philippines. CytoDyn has been supplying leronlimab to the Philippines as a therapeutic treatment for critically ill COVID-19 patients under Compassionate Special Permits (CSPs) authorized by the Philippine FDA. Appearing in this news program will be Nader Pourhassan, PhD, CytoDyn’s President and Chief Executive Officer, Chris Recknor, MD, CytoDyn’s Chief Operating Officer and Head of Clinical Development, Harish Seethamraju, MD, Medical Director for the Mount Sinai Lung Transplantation Program in New York, and Richard Nicolas, MD, Associate Clinical Professor for Cardiothoracic and Vascular Surgery, University of the Philippines, and practicing surgeon, St. Luke’s Medical Center, Philippines.This news event can be accessed as follows: Date: Sunday, May 9, 2021; Time: 5:00 pm to 6:00 pm PDT / 8:00 pm to 9:00 pm EDT. Viewers are encouraged to login 30 minutes prior to the start time. Social media: Facebook: http://facebook.com/onenewsph; YouTube: http://youtube.com/onenewsph
Login Or Register To Read Full Story